GALECTIN THERAPEUTICS INC. (GALT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -15.62M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 8.91M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-15.62M | (m) | (m) | $8.91M | (m) | (m) |
| 2026-03-31 | $-16.27M | (m) | (m) | $10.04M | (m) | (m) |
| 2025-12-31 | $-20.09M | (m) | (m) | $14.29M | (m) | (m) |
| 2025-09-30 | $-29.15M | (m) | (m) | $23.47M | (m) | (m) |
| 2025-06-30 | $-34.02M | (m) | (m) | $28.45M | (m) | (m) |
| 2025-03-31 | $-40.68M | (m) | (m) | $35.00M | (m) | (m) |
| 2024-12-31 | $-42.43M | (m) | (m) | $36.57M | (m) | (m) |
| 2024-09-30 | $-39.57M | (m) | (m) | $33.69M | (m) | (m) |
| 2024-06-30 | $-39.67M | (m) | (m) | $33.83M | (m) | (m) |
| 2024-03-31 | $-37.38M | (m) | (m) | $31.39M | (m) | (m) |
| 2023-12-31 | $-38.07M | (m) | (m) | $32.13M | (m) | (m) |
| 2023-09-30 | $-39.14M | (m) | (m) | $32.91M | (m) | (m) |
| 2023-06-30 | $-38.10M | (m) | (m) | $31.77M | (m) | (m) |
| 2023-03-31 | $-38.76M | (m) | (m) | $32.48M | (m) | (m) |
| 2022-12-31 | $-38.35M | (m) | (m) | $31.74M | (m) | (m) |
| 2022-09-30 | $-35.14M | (m) | (m) | $28.59M | (m) | (m) |
| 2022-06-30 | $-35.27M | (m) | (m) | $28.60M | (m) | (m) |
| 2022-03-31 | $-33.80M | (m) | (m) | $26.98M | (m) | (m) |
| 2021-12-31 | $-30.18M | (m) | (m) | $23.82M | (m) | (m) |
| 2021-09-30 | $-30.59M | (m) | (m) | $24.33M | (m) | (m) |
| 2021-06-30 | $-28.27M | (m) | (m) | $22.50M | (m) | (m) |
| 2021-03-31 | $-26.18M | (m) | (m) | $20.73M | (m) | (m) |
| 2020-12-31 | $-23.44M | (m) | (m) | $17.98M | (m) | (m) |
| 2020-09-30 | $-20.80M | (m) | (m) | $15.40M | (m) | (m) |
| 2020-06-30 | $-17.74M | (m) | (m) | $12.12M | (m) | (m) |
| 2020-03-31 | $-14.65M | (m) | (m) | $8.96M | (m) | (m) |
| 2019-12-31 | $-13.44M | (m) | (m) | $7.47M | (m) | (m) |
| 2019-09-30 | $-11.23M | (m) | (m) | $4.86M | (m) | (m) |
| 2019-06-30 | $-11.05M | (m) | (m) | $4.87M | (m) | (m) |
| 2019-03-31 | $-11.79M | (m) | (m) | $4.82M | (m) | (m) |
| 2018-12-31 | $-13.60M | (m) | (m) | $6.47M | (m) | (m) |
| 2018-09-30 | $-12.99M | (m) | (m) | $6.28M | (m) | (m) |
| 2018-06-30 | $-14.72M | (m) | (m) | $8.28M | (m) | (m) |
| 2018-03-31 | $-15.48M | (m) | (m) | $10.25M | (m) | (m) |
| 2017-12-31 | $-16.25M | (m) | (m) | $11.72M | (m) | (m) |
| 2017-09-30 | $-18.47M | (m) | (m) | $14.15M | (m) | (m) |
| 2017-06-30 | $-18.60M | (m) | (m) | $13.94M | (m) | (m) |
| 2017-03-31 | $-19.61M | (m) | (m) | $14.72M | (m) | (m) |
| 2016-12-31 | $-21.48M | (m) | (m) | $15.32M | (m) | (m) |
| 2016-09-30 | $-21.57M | (m) | (m) | $14.81M | (m) | (m) |
| 2016-06-30 | $-22.93M | (m) | (m) | $15.98M | (m) | (m) |
| 2016-03-31 | $-22.05M | (m) | (m) | $14.36M | (m) | (m) |
| 2015-12-31 | $-20.08M | (m) | (m) | $13.11M | (m) | (m) |
| 2015-09-30 | $-19.13M | (m) | (m) | $12.28M | (m) | (m) |
| 2015-06-30 | $-16.71M | (m) | (m) | $9.79M | (m) | (m) |
| 2015-03-31 | $-15.43M | (m) | (m) | $8.79M | (m) | (m) |
| 2014-12-31 | $-15.43M | (m) | (m) | $8.43M | (m) | (m) |
| 2014-09-30 | $-14.50M | (m) | (m) | $7.74M | (m) | (m) |
| 2014-06-30 | $-14.57M | (m) | (m) | $6.95M | (m) | (m) |
| 2014-03-31 | $-13.74M | (m) | (m) | $6.71M | (m) | (m) |
| 2013-12-31 | $-12.10M | (m) | (m) | $5.69M | (m) | (m) |
| 2013-09-30 | $-11.68M | (m) | (m) | $5.29M | (m) | (m) |
| 2013-06-30 | $-11.03M | (m) | (m) | $5.51M | (m) | (m) |
| 2013-03-31 | $-11.15M | (m) | (m) | $5.38M | (m) | (m) |
| 2012-12-31 | $-9.90M | (m) | (m) | $4.53M | (m) | (m) |
| 2012-09-30 | $-10.89M | (m) | (m) | $4.39M | (m) | (m) |
| 2012-06-30 | $-10.03M | (m) | (m) | $3.63M | (m) | (m) |
| 2012-03-31 | $-10.35M | (m) | (m) | $3.71M | (m) | (m) |
| 2011-12-31 | $-10.41M | (m) | (m) | $3.55M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-4.88M | (m) | (m) | $1.07M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |